Highlights

  • IDT Australia shares rose 4.88% to AUD 0.043 on 28 April 2026, following the release of its quarterly update.
  • Q3-FY26 Operating Revenue declined 25.2% year-on-year and 37.7% quarter-on-quarter to AUD 2.6 million due to seasonal factors and shutdowns.
  • FY26 EBITDA loss forecast to narrow significantly to between AUD 1.5 million and AUD 2 million, improving 68%–76% from FY25.
  • Full-year Revenue from core verticals expected to reach AUD 15 million to AUD 16 million, representing 4%–11% growth.
  • IDT designated as a Preferred Vendor by Sanofi, opening access to broader global opportunities.
  • Recommissioned facilities and strategic partnerships expected to support improved performance in Q4-FY26.

IDT Australia Ltd (ASX:IDT) shares moved 4.88% higher to AUD 0.043 during the morning session on 28 April 2026, following the release of its March quarter update and revised FY26 guidance. While the stock remains down 60.91% over the past year, the latest update reflects improving Earnings visibility and a narrowing loss profile, which appears to be supporting investor sentiment in today’s trade.

IDT Australia is a pharmaceutical Manufacturing company based in Boronia, Victoria, specialising in high potency and high containment products. The company operates cGMP-compliant facilities that are regularly audited by regulatory bodies such as the US FDA and the Australian TGA. Its capabilities span early-stage Drug Development, scale-up, active pharmaceutical ingredient (API) Manufacturing, and finished dose production across oral and injectable formats. With a focus on servicing both domestic and international clients, the company has been undergoing a strategic transformation aimed at improving profitability and operational efficiency.

Quarterly Performance Impacted by Seasonal Factors

For the three months ended 31 March 2026 (Q3-FY26), IDT reported total Operating Revenue of AUD 2.6 million. This represented a decline of 25.2% compared to the previous corresponding period and a 37.7% drop from the prior quarter. The company attributed this reduction primarily to a scheduled maintenance shutdown and the commissioning of key Manufacturing facilities, alongside the impact of seasonal public holidays.

Despite the softer quarterly performance, year-to-date Revenue remains 6% ahead of the prior year, indicating underlying Business activity has continued to progress. The company highlighted that the temporary disruption associated with Facility upgrades is expected to support improved production capacity and efficiency in subsequent periods.

FY26 Outlook Points to Earnings Improvement

A key takeaway from the update is the company’s revised outlook for FY26. IDT expects its EBITDA loss to narrow significantly to a range of AUD 1.5 million to AUD 2 million, compared to a loss of AUD 6.3 million in FY25. This represents an improvement of approximately 68% to 76%, reflecting the impact of its ongoing strategic realignment and cost optimisation initiatives.

Revenue from the company’s three operating verticals—API Manufacturing, Specialty Orals, and Advanced Therapies—is projected to reach between AUD 15 million and AUD 16 million for FY26. This implies growth of 4% to 11% compared to FY25. Total Revenue, including disbursements, is expected to range between AUD 18 million and AUD 19 million.

The company also indicated that it anticipates delivering its strongest fourth-quarter performance since the commencement of its transformation program over two years ago, suggesting a more favourable operational trajectory heading into the final quarter of the financial year.

Strategic Realignment and Business Model Evolution

IDT’s ongoing transformation strategy is centred on improving Cash Flow and targeting higher-value, repeatable work. This includes optimising resource allocation and focusing on customers with the capacity to generate long-term contracts across multiple Business segments.

As part of this approach, the company is working to re-establish API Manufacturing as a core pillar of its operations. While API-related Revenue declined in the March quarter due to contract progression into other verticals, management expects a rebound in activity in the current quarter.

The Specialty Orals segment is being refined with a focus on radiopharmaceuticals, while continuing to support Demand from medicinal cannabis and psychedelic drug programs. Meanwhile, the Advanced Therapies (Sterile Fill) Business is being positioned to capture higher-value opportunities, particularly in emerging areas such as mRNA technologies.

Sanofi Partnership Enhances Global Opportunity Pipeline

During the quarter, IDT achieved a notable milestone by being designated as a Preferred Vendor by global pharmaceutical company Sanofi. This recognition follows a successful collaboration on mRNA Vaccine development and provides IDT with the opportunity to participate in additional programs across Sanofi’s global operations.

The designation allows IDT to submit proposals across multiple therapeutic areas and dosage forms, potentially expanding its exposure to international pharmaceutical projects. This development is expected to contribute to future Revenue opportunities as the company continues to build relationships with large-scale clients.

Policy Developments Supporting Specialty Orals Demand

The company also highlighted favourable regulatory developments in the United States, particularly in relation to psychedelic-assisted therapies and cannabinoid-based medicines. Recent policy direction aimed at reducing barriers to these treatments is contributing to increased Investment and activity in the sector.

IDT noted that it has already secured new work from a controlled-drug manufacturer targeting US market opportunities. These developments are expected to support Demand for the company’s API and Specialty Orals services over the coming months.

Recommissioned Facilities Begin Delivering Benefits

A significant component of IDT’s transformation program has been the recommissioning of previously inactive Manufacturing Assets. This includes a 4,000-litre API plant and key sterile Fill-finish capabilities.

The company is now beginning to realise the benefits of these investments, which include improved production flexibility, reduced marginal costs, and enhanced competitiveness in bidding for global contracts. Increased utilisation of these facilities is already being observed, supporting expectations for a stronger Q4-FY26 performance.

The ability to operate multiple Manufacturing streams simultaneously also positions IDT to pursue higher-Margin opportunities that were previously constrained by capacity limitations.

Global Outreach Through Strategic Industry Partnerships

IDT has also entered into a Partnership with Fierce Pharma to expand its presence in global pharmaceutical and biotechnology markets. As part of this initiative, the company will participate in industry events such as Fierce Biotech Week in Boston, providing access to senior decision-makers and potential clients.

Additionally, a dedicated event hosted by Fierce Pharma will allow IDT to showcase its capabilities to procurement and technical leaders across the industry. Sanofi’s participation in support of IDT at this event is expected to further validate the company’s capabilities and enhance its credibility within the sector.

What This Means for Investors?

The latest update from IDT Australia reflects a mixed operational picture in the near term, with Q3-FY26 performance impacted by planned shutdowns and commissioning activities. However, the broader outlook indicates a shift towards improved Earnings, supported by cost optimisation, Facility upgrades, and strategic partnerships.

The forecast reduction in EBITDA losses, combined with expectations for a stronger fourth quarter and continued Revenue growth, appears to be contributing to today’s share price movement. Developments such as the Sanofi Preferred Vendor status and expanding exposure to emerging therapeutic segments further highlight potential growth pathways.

While the company remains in a recovery phase, the progression of its strategic initiatives and improving financial metrics are key areas being monitored by Market Participants.